



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems**  
**UNIFORM PRACTICE ADVISORY (UPC #05-26) 01/09/2026 Histogen, Inc.**  
**(HSTOQ)**

Notice has been received that the above Company's Amended Subchapter V Plan became effective on 12/16/2024. Pursuant to the plan, In the event Treatment B applies to Class 3 General Unsecured Creditors, each holder of an Allowed Equity Interest shall receive one or more Distributions on a Distribution Date, as determined by the Plan Administrator, in an amount equal to its Pro Rata Share of the Available Cash remaining after payment of Allowed Claims in Classes 1, 2, and 3, Allowed Administrative Claims (including Allowed Professional Fee Claims), and Allowed Priority Tax Claims. See the Company's Amended Subchapter V Plan for more details.<sup>1</sup>

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

---

<sup>1</sup> See *e.g., In re: Histogen, inc., et al., Debtors*. Chapter 11 Case No. 24-01357 (JBM) (Subchapter V) Amended Subchapter V Plan of Histogen, Inc. and Debtor Affiliates.